Cerebrovascular DiseaseNCT07335029
Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outcomes of Intracranial Dissecting Aneurysm
An observational study of Cerebrovascular Disease and Intracranial Aneurysm, run by Beijing Neurosurgical Institute at 1 site in China.
Trial summary
This study aims to conduct a comprehensive analysis by integrating clinical factors, aneurysm morphological characteristics, and factors reflecting pathophysiological processes (such as hemodynamic and radiomics features), in order to explore the hemodynamic mechanisms associated with the progression of intracranial… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Cerebrovascular Disease, Intracranial Aneurysm, Intracranial Arterial Dissection
- How many people
- 208 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2023to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The target population consists of patients with intracranial artery dissection (IAD) who received care at the study institution between 2015 and 2025. Eligible participants are adults aged 18-80 years with IAD confirmed by both digital subtraction angiography (DSA) and high-resolution MRI (HR-MRI) according to the imaging diagnostic criteria proposed in the Chinese expert consensus on intracranial artery dissection. Participants are managed with conservative treatment and undergo follow-up, and they provide written informed consent. Key exclusions include arteritis, fibromuscular dysplasia, iatrogenic or traumatic pseudoaneurysm; contraindications to MRI or cerebral angiography (e.g., implanted metallic foreign bodies, claustrophobia, or iodinated contrast allergy); extracranial dissection extending intracranially or concomitant intracranial atherosclerotic plaque in the affected vessel; refusal of MRI; severe comorbidities with an expected survival of less than 2 years; or absence of
Who may be able to join
- Intracranial dissecting aneurysm clearly diagnosed by DSA and high-resolution MRI imaging (according to the imaging diagnostic criteria proposed in the Chinese Expert Consensus on Imaging Diagnosis of Intracranial Arterial Dissection)
- patients managed with conservative treatment and follow-up
- patients who agree and sign a written informed consent form
Who cannot join
- Arteritis, fibromuscular dysplasia, iatrogenic or traumatic pseudoaneurysms
- Contraindications to MRI examination (such as claustrophobia or metallic implants), or contraindications to cerebral angiography (such as iodine contrast allergy)
- Dissecting aneurysms extending from the extracranial segment to the intracranial segment, or cases with concomitant intracranial atherosclerotic plaques in the affected vessels
- Patients who refuse MRI examination
- Patients with severe comorbid diseases and an expected survival time of less than 2 years due to these conditions
- Patients without follow-up HR-MRI imaging for any reason
Trial locations and contacts
1 site in 1 country.
China1 site
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 107000
About this study
This study aims to conduct a comprehensive analysis by integrating clinical factors, aneurysm morphological characteristics, and factors reflecting pathophysiological processes (such as hemodynamic and radiomics features), in order to explore the hemodynamic mechanisms associated with the progression of intracranial dissecting aneurysms. Furthermore, artificial intelligence algorithms will be employed to develop and validate an intelligent risk prediction model for the progression and outcomes of intracranial dissecting aneurysms.
- Medical subject headings
- Cerebrovascular Disorders, Intracranial Aneurysm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Control Group (Non-progression Group) | Imaging progression of intracranial dissecting aneurysms during follow-up | |
| Experimental Group (Progression Group) | Imaging progression of intracranial dissecting aneurysms during follow-up |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression of intracranial dissecting aneurysms
Measured: From enrollment to 12 months of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start1 Jan 2023
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cerebrovascular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 208 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Neurosurgical Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Li wenqiang, Beijing Neurosurgical Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07335029
- Sponsor's protocol ID
- KY2024-315-02
- Status last verified
- Jan 2026
- First submitted
- 4 Jan 2026
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: To protect patient privacy, the decision was made not to share the data.
Publications
Li W, Liu J, Zhang Y, Wang K, Tian Z, Zhang Q, Jiang C, Yang X, Wang Y. Flow Diversion and Outcomes of Vertebral Fusiform Aneurysms After Stent-Only Treatment: A Hemodynamic Study. World Neurosurg. 2017 Nov;107:202-210. doi: 10.1016/j.wneu.2017.07.157. Epub 2017 Aug 4.
PubMed 28826706Zhang Y, Tian Z, Zhu W, Liu J, Wang Y, Wang K, Zhang Y, Yang X, Li W. Endovascular treatment of bilateral intracranial vertebral artery aneurysms: an algorithm based on a 10-year neurointerventional experience. Stroke Vasc Neurol. 2020 Sep;5(3):291-301. doi: 10.1136/svn-2020-000376. Epub 2020 Aug 13.
PubMed 32792460
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outcomes of Intracranial Dissecting Aneurysm
- ClinicalTrials.gov ID
- NCT07335029
- Acronym / sponsor ID
- KY2024-315-02
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 208 participants (estimated)
- Lead sponsor
- Beijing Neurosurgical InstituteUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to conduct a comprehensive analysis by integrating clinical factors, aneurysm morphological characteristics, and factors reflecting pathophysiological processes (such as hemodynamic and radiomics features), in order to explore the hemodynamic mechanisms associated with the progression of intracranial dissecting aneurysms. Furthermore, artificial intelligence algorithms will be employed to develop and validate an intelligent risk prediction model for the progression and outcomes of intracranial dissecting aneurysms.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Group (Non-progression Group) | – | –Imaging progression of intracranial dissecting aneurysms during follow-up |
| Experimental Group (Progression Group) | – | –Imaging progression of intracranial dissecting aneurysms during follow-up |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The target population consists of patients with intracranial artery dissection (IAD) who received care at the study institution between 2015 and 2025. Eligible participants are adults aged 18-80 years with IAD confirmed by both digital subtraction angiography (DSA) and high-resolution MRI (HR-MRI) according to the imaging diagnostic criteria proposed in the Chinese expert consensus on intracranial artery dissection. Participants are managed with conservative treatment and undergo follow-up, and they provide written informed consent. Key exclusions include arteritis, fibromuscular dysplasia, iatrogenic or traumatic pseudoaneurysm; contraindications to MRI or cerebral angiography (e.g., implanted metallic foreign bodies, claustrophobia, or iodinated contrast allergy); extracranial dissection extending intracranially or concomitant intracranial atherosclerotic plaque in the affected vessel; refusal of MRI; severe comorbidities with an expected survival of less than 2 years; or absence of
Key inclusion criteria (3 listed)
- Intracranial dissecting aneurysm clearly diagnosed by DSA and high-resolution MRI imaging (according to the imaging diagnostic criteria proposed in the Chinese Expert Consensus on Imaging Diagnosis of Intracranial Arterial Dissection)
- patients managed with conservative treatment and follow-up
- patients who agree and sign a written informed consent form
Key exclusion criteria (6 listed)
- Arteritis, fibromuscular dysplasia, iatrogenic or traumatic pseudoaneurysms
- Contraindications to MRI examination (such as claustrophobia or metallic implants), or contraindications to cerebral angiography (such as iodine contrast allergy)
- Dissecting aneurysms extending from the extracranial segment to the intracranial segment, or cases with concomitant intracranial atherosclerotic plaques in the affected vessels
- Patients who refuse MRI examination
- Patients with severe comorbid diseases and an expected survival time of less than 2 years due to these conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Progression of intracranial dissecting aneurysms
Time frame: From enrollment to 12 months of follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
- Results publication: PubMed 28826706Li W, Liu J, Zhang Y, Wang K, Tian Z, Zhang Q, Jiang C, Yang X, Wang Y. Flow Diversion and Outcomes of Vertebral Fusiform Aneurysms After Stent-Only Treatment: A Hemodynamic Study. World Neurosurg. 2017 Nov;107:202-210. doi: 10.1016/j.wneu.2017.07.157. Epub 2017 Aug 4.
- Results publication: PubMed 32792460Zhang Y, Tian Z, Zhu W, Liu J, Wang Y, Wang K, Zhang Y, Yang X, Li W. Endovascular treatment of bilateral intracranial vertebral artery aneurysms: an algorithm based on a 10-year neurointerventional experience. Stroke Vasc Neurol. 2020 Sep;5(3):291-301. doi: 10.1136/svn-2020-000376. Epub 2020 Aug 13.
- Individual participant dataSharing planned: No. To protect patient privacy, the decision was made not to share the data.
Related trials for Cerebrovascular Disease
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebrovascular Disease and Intracranial Aneurysm, run by Beijing Neurosurgical Institute at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression of intracranial dissecting aneurysms (time frame: From enrollment to 12 months of follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07335029, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.